恩替卡韦治疗失代偿期乙肝肝硬化临床疗效观察

观察恩替卡韦对失代偿期乙肝肝硬化患者的治疗效果和安全性。20例乙肝肝硬化失代偿期患者予恩替卡韦0.5mg,每天1次口服,持续治疗48周。观察治疗后12周、24周、48周病毒学、生化指标、凝血酶原活动度及Child-Pugh积分等变化情况。患者治疗前血清HBV DNA对数值平均为7.45±0.38 log拷贝/ml,在接...

Therapeutic Effects of Entecavir Therapy for Patients with Hepatitis B Virus Related Decompensated Cirrhosis

To evaluate the efficacy and safety of Entecavir in patients with hepatitis B virus（HBV） related decompensated cirrhosis.In this study,20 patients with HBV related decompensated cirrhosis received 0.5 mg of Entecavir once daily for 48 weeks.HBV DNA,ALT,AST,TBIL,PTA,and Child-Pugh score were quantified at baseline and at 12,24,48 weeks.The mean levels of serum HBV DNA was 7.45±0.38 log10 at baseline.At week 12,24 and 48 weeks,the mean levels of serum HBV DNA were 4.71±0.44 log10（P0.01）,3.74±0.56 log10（P0.01）,2.83±0.21 log10（P0.01）.（Undetectable serum HBV DNA level was 500 copies/ml）.At week 48 of treatment,levels of alanine amiotransferase（ALT）,aspartate transaminase（AST）,and total bilirubin（TBIL） and Child-Pugh score decreased significantly;levels of albubin（ALB） increased significantly.The 48-week Entecavir treatment resulted in virologic suppression.The Entecavir treatment could decrease the level of HBV DNA,improve liver function,inhibit HBV replication in patients with HBV related cirrhosis.In treatment of the patients with HBV related cirrhosis,Entecavir is potent to suppress HBV replication and delay progression of fibrosis.